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Abstract: The objective of the study was to develop baicalin loaded liquid self-nanoemulsifying drug
delivery systems (BSNEDDS) and to characterize them by physicochemical methods in order to optimize
the composition and quality attributes. Atomic force microscopy (AFM) was utilized to evaluate
the morphological characteristics and size distribution of reconstituted nanoemulsion droplets with
a new sample preparation method for the elucidation of individual nanodroplets without any signs of
coalescence. Response surface methodology and desirability approach was used to select the optimized
composition related to droplet size, zeta-potential, polydispersity index (PDI), and turbidity characteristics.
Droplet size distribution measured by dynamic light scattering method was highly desirable with
52.87 ± 0.5322 nm, which was confirmed by AFM imaging. The optimized formula contains Peceol®
(14.29%, w/w), Kolliphor® EL (57.14%, w/w), and Transcutol® P (28.57%, w/w). Long-term stability
analysis did not show any significant change in droplet size or PDI over the investigated period. More than
40.5-times solubility improvement was achieved with the optimized BSNEDDS correlated to solubility
of baicalin in distilled water. In vitro dissolution studies at pH 1.2 and pH 6.8 were performed and
revealed that the optimized BSNEDDS formula showed pH independent drug dissolution, and 100% of
incorporated baicalin dissolved within five minutes in rapidly dispersing nanodroplets.
Keywords: baicalin; self-nanoemulsifying system; atomic force microscopy; solubility improvement;
graphical optimization; dynamic light scattering
1. Introduction
Scutellaria baicalensis Georgi (S. baicalensis G.) is one of the fundamental herbs in traditional Chinese
herbal medicine known as Huang Qin [1]. The root is officially listed in the Chinese Pharmacopoeia
and was assumed in European Pharmacopoeia (Ph.Eur.) 9th Edition (Ph. Eur. 9., 2018 [2]). The major
components of the dried root are baicalin (D-glucuronic acid-5,6-dihydroxyflavone) and its aglycone,
baicalein (5,6,7-trihydroxyflavone) [3]. In the scientific literature we can find numerous studies carried out
showing that baicalin and its aglycone were effective medical agents with a variety of pharmacological
activities such as anti-oxidant, anti-tumor, anti-ischemic, and anti-inflammatory effects [4].
Baicalin belongs to Class IV of the Biopharmaceutical Classification System (BCS) due to
the extremely low water solubility (0.054 mg/mL) and lipophilicity (Papp = 0.037 × 10−6 cm/s,
logP = 1.29) [5]. It is a weak acidic compound, with pKa values of 7.6 and 10.1 [6]. It can be seen from
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the chemical structure that both the glucuronide and flavone parts form intramolecular H-bonds, which
can be responsible for the extremely poor water solubility and high melting point [7]. The stability of
baicalin was evaluated in buffered aqueous solutions at different pHs (2.0, 3.0, 4.5, 6.8, 7.4, and 9.0) and
temperatures (4, 25, and 40 ◦C). An acidic environment and low temperature were protective factors for
the long term stability of this compound [8]. The absolute bioavailability of baicalin was 2.2± 0.2% after
intravenous and oral administration to intact rats. It undergoes extensive intestinal glucuronidation
and the fraction of baicalin and its conjugated metabolites excreted in urine appear to be negligible
compared with the biliary excretion [9]. Different ATP-binding cassette (ABC) transporters were
identified, which interfere in the enterohepatic recirculation of baicalin [10]. Various formulations were
developed to counterbalance the low oral bioavailability of the drug. Solid dispersions, cyclodextrins,
nanoemulsions, liposomes, and PEGylated lipid nanoparticles have already been investigated [11].
A baicalin-loaded nanohydrogel formulation showed promising performances in the topical treatment
of skin wounds [12].
In recent years, Self-Emulsifying Drug Delivery Systems (SEDDS) have become an increasingly
effective possibility for improving the oral bioavailability of poorly water-soluble drugs [13].
Self-emulsifying formulations are isotropic mixtures of natural or synthetic oils, lipophilic or hydrophilic
surfactants, co-solvent(s) of the poorly water-soluble drug. These anhydrous preconcentrates spontaneously
form oil-in-water emulsions upon mild agitation in the stomach [14]. Due to the numerous combination
possibilities of different excipients, the Lipid Formulation Classification System (LFCS) was established by
Pouton et al. in 2000 [15]. The LFCS classifies lipid-based formulations into four types according to their
composition, droplet size, and characteristic features [15].
SEDDS can form colloidal micro/nanoemulsions (r < 100 nm) after dilution in the gastrointestinal
tract (GIT) [16]. It is important to accurately specify the kind of colloidal dispersion used in a study,
because this influences the physicochemical and functional properties. There are a lot of similarities
between micro- and nanoemulsions (e.g., composition, fabrication, structure), but some differences
can help distinguish between them [17]. The most significant difference between nanoemulsions and
microemulsions is in terms of their thermodynamic stabilities. From a thermodynamic point of view,
nanoemulsions are thermodynamically unstable, whereas microemulsions are thermodynamically
stable systems [18]. There are numerous physicochemical phenomena which can lead to the breakdown
of a nanoemulsion (e.g., creaming, flocculation, Ostwald ripening) [19]. By incorporating substances
known as stabilizers, such as surfactants, texture modifiers, weighting agents, or ripening retarders,
the long-term stability of nanoemulsions can be enhanced [20]. Although the physicochemical
characterization of SEDDS and nanodroplets are well-known considering particle size distribution,
zeta-potential, polydispersity index (PDI), turbidity, dilution robustness, and drug release, atomic
force microscopy (AFM) had not yet been used for the morphological imaging of drug loaded
nanodroplets [21,22]. We developed and optimized baicalin loaded self-nanoemulsifying drug delivery
systems (BSNEDDS), which can overcome the limitations of conventional nanoemulsions, such as
low patient compliance (poor palatability), unsuitability for delivery through hard or soft gelatine
capsules (high water content), larger volume, and ambiguous long-term storage. SNEDDS provide
easy manufacture and ability to scale, improved physical and chemical stability, and better patient
compliance [23].
The aim of the study was to enhance the poor aqueous solubility and dissolution rate of baicalin
via a liquid self-nanoemulsifying drug delivery system. Our scope was to find an optimized carrier
system for baicalin, and to analyze and characterize the reconstituted nanoemulsion using AFM,
droplet size, and Zeta-potential measurements, long-term stability tests, and in vitro dissolution
studies. The development of a sample preparation method for AFM imaging of nanosized droplets
was also in our interest.
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2. Materials and Methods
2.1. Materials
Baicalin (batch number: BA-16118) was supplied by Actin Chemicals, Inc. (Chengdu, China).
The following materials were kindly donated by Gattefossé (Saint Priest, France) and were used as
received: Capryol® 90 (Propylene glycol monocaprylate), Labrafac™ Lipophile WL 1349 (Medium-chain
triglycerides), Labrafil® M 1944 CS (Oleoyl polyoxyl-6 glycerides), Labrasol® (Caprylocaproyl
polyoxyl-8 glycerides), Lauroglycol™ 90 (Propylene glycol monolaurate), Maisine® CC (Glyceryl
monolinoleate), Peceol™ (Glyceryl monooleate (type 40)), Transcutol® P (Dyethylene glycol monoethyl
ether). Kolliphor® EL (Polyoxyl 35 hydrogenated castor oil), Kolliphor® RH40 (Polyoxyl 40 hydrogenated
castor oil), olive oil, and Emprove® (Absolute ethanol) were purchased from Sigma Aldrich (St. Louis, MO,
USA). Sunflower oil was supplied by Hungaropharma (Budapest, Hungary). Distilled water was prepared
freshly whenever required. All other chemicals were of reagent grade.
2.2. Solubility Studies
The thermodynamic solubility of baicalin was determined in distilled water, different oils,
emulgents, and co-emulgents by saturation shake-flask method with minor modifications [24].
Firstly, an excess amount of baicalin was added to 2 g of each excipient in sealed vials. All samples
were stirred (approx. 500 rpm) and thermostated (IKA RT-5 power heatable magnetic stirrer, IKA
Work Inc., Wilmington, DE, USA) at 37 ± 1 ◦C for 24 h. Secondly a cycle of sedimentation (to achieve
separation of the excess solid from the solution) was carried out for 24 h at 37 ± 1 ◦C. To improve
the efficacy of phase-separation, the saturated supernatant of samples was centrifuged at 14,000 rpm
for 15 min using a centrifuge (Herolab MicroGen 16, Herolab GmbH, Wiesloch, Germany) followed
by removal of the incidentally undissolved baicalin from the supernatant by filtering it with a nylon
membrane filter (0.22 µm, 25 mm, FilterBio® NY, Labex Ltd., Budapest, Hungary). Samples were
suitably diluted with absolute ethanol and drug concentration was obtained via UV spectroscopy
at wavelength 279 nm using equivalent proportions of excipients as blank (Agilent 8453 UV-Visible
Spectrophotometer, Agilent Technologies Ltd., Santa Clara, CA, USA). All experiments were repeated
three times and results were calculated from the linear calibration of baicalin in absolute ethanol
(R2 = 0.9991). Data are expressed as mean ± SD (µg/mL).
2.3. Screening of Surfactants for Emulsifying Ability
Various surfactants (Capryol® 90, Kolliphor® EL, Kolliphor® RH 40, Labrafil® M 1944 CS,
Labrasol®, Lauroglycol™ 90) were screened for emulsification ability with the selected oily compound.
According to pre-formulation experiments, different oil:emulgent w/w ratios (1:3, 1:4, 1:5, 1:6) were
created, and selection of the emulgent was based on the results of droplet size and transmittance
analysis. Briefly, 1 g of pre-concentrate was prepared in sufficient quantities, gently stirred,
and heated to 37 ± 1 ◦C, promoting the homogenization process. The isotropic mixture, 0.1 mL,
which was accurately weighed and diluted to 100 mL with distilled water, yielded fine emulsions.
Emulsions were equilibrated for 2 h at room temperature before measuring their transmittance
by Agilent 8453 UV-Visible Spectrophotometer at wavelength 633 nm using distilled water as
blank. The droplet size (Z-avg) distributions and polydispersity indices were measured by DLS
(dynamic light scattering) method with the instrument Zetasizer Nano ZS™ (Malvern Instruments Ltd.,
Malvern, UK). Measurement settings were: automatic mode, NIBS (none-invasive-back-scattering)
173◦, 30 sub runs/measurements, run duration of 10 s, automatic laser position selected, 4.65 mm
position from the bottom of the cuvette, attenuation setting of attenuator 9 was selected automatically.
Five measurements with 30 runs were performed for every sample and the mean ± SD values are
reported in this article for all DLS parameters, including intensity-weighted mean hydrodynamic
diameters (Z-avg) and polydispersity indices (PDI).
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2.4. Construction of Ternary Phase Diagram
In order to identify the self-nanoemulsifying compositions with the desired droplet size
(Z-avg < 200 nm), a ternary phase diagram was constructed [25]. For every mixture, the surfactant and
co-surfactant (Smix) ratios were varied from 1:1, 1:2, 1:3, and 2:1. 2 g of the oil and Smix in different w/w
ratios (1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, and 2:1) were measured, blended for 1 h at approximately
500 rpm (IKA RT-5 power heatable magnetic stirrer), and heated at 37± 1 ◦C. Compositions were evaluated
for nanoemulsion formation by dropping 100 µL of each of the 40 mixtures in glass beakers containing
100 mL distilled water that was maintained at 37 ± 1 ◦C, followed by Z-avg measurements (for setting
parameters see Section 2.3). All experiments were repeated three times and the ternary phase diagram was
constructed using the ProSim ternary diagram drawing application (ProSim, Toulouse, France).
2.5. Preparation of Self-Nanoemulsifying Formulations without (SNEDDS) and with Baicalin (BSNEDDS)
In all cases, oil, emulgent, and co-emulgent were thermostated at 37 ± 1 ◦C and stirred
(approximately 500 rpm) in different w/w ratios by a heatable magnetic stirrer. After a 1-h
homogenization cycle, they were stored at room temperature in sealed vials until further use.
BSNEDDS were prepared by the above-mentioned method, but at the end of the homogenization cycle,
5 mg of baicalin was added to 2 mL of the pre-concentrate (C = 2.5 mg/mL).
2.6. Optimization of SNEDDS Pre-concentrates
In order to reduce the number of trials needed in the optimization of SNEDDS formulation, and to
characterize the relationship between the formulation factors and the output variables, a response
surface methodology based on Face Centered Central Composite Design was utilized. The amount
of oil and Smix ratio can significantly influence the quality and performance of a nanoemulsion,
so different oil:Smix (1:8, 1:6, 1:4) ratios and emulgent:co-emulgent (1:1, 2:1, 3:1) ratios were analyzed
as formulation variables (X1, X2). In the study, a three-level (coded as +1, 0, −1) factorial design
for the optimization of two variables with 13 runs (5 center points) was applied. Droplet size (Y1),
transmittance (Y2), zeta-potential (Y3), and PDI (Y4) were selected as responses. Experiments were run
in random order to increase the predictability of the model. The modelling of corresponding response
surfaces was carried out using second order models, which can describe the surface curvature with the
following polynomial equation:
Y = b0 + b1x1 + b2x2 + b12x1x2 + b11x21 + b22x
2
2 (1)
where Y is the dependent variable; b0 the intercept is the arithmetic average of all quantity outcomes
of 13 runs; x are the independent variables (x1 oil:Smix ratio, x2 emulgent:co-emulgent ratio) and b
parameters mark the regression coefficients characterizing the main (b1, b2), the quadratic (b11, b22),
and the interaction effects (b12).
A substantial goal of an optimization process is to find the most desirable set of conditions.
Optimization of multiple responses was carried out by graphical optimization, which set minimum
or maximum limits for each response then created an overlay graph highlighting an area of desired
operability. The optimization and statistical experiments were designed and evaluated using the
Design-Expert® software, version 7.0.0 (Stat-Ease® Inc., Minneapolis, MN, USA, 2005).
2.7. Characterization of Optimized BSNEDDS
2.7.1. Droplet size, Transmittance, PDI, and Zeta-Potential Measurements
Droplet size, transmittance, and PDI were determined according to Section 2.3. Zeta-potential was
measured using the Zetasizer Nano ZS™ (Malvern Instruments Ltd., Malvern, UK) by diluting 0.1 mL
of optimized BSNEDDS with 100 mL of distilled water. The evaluation was based on Laser Doppler
Micro-electrophoresis using the Smoluchowski model. The selection of the attenuator level and the
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position of the optics was set automatically. The instrument was operated by automatic selection of
voltage based on the measured conductivity of the sample. The analysis was carried out at 37.0 ◦C in
clear, disposable folded-capillary zeta cells. Five measurements with minimum 10 runs/sample were
performed for each sample, the mean values ± SD (mV) are reported.
2.7.2. Determination of the Thermodynamic Solubility of Baicalin in Optimized SNEDDS
2 g of selected oil, emulgent, and co-emulgent were thermostated and homogenized (37 ◦C,
approximately 500 rpm, 1 h) in optimized ratios by a heatable magnetic stirrer. An excess amount of
pure baicalin was added to the best pre-concentrate in sealed vials. Henceforth, the investigation was
fulfilled as detailed in Section 2.2.
2.7.3. Cloudpoint Measurement
Cloudpoint is the temperature above which an aqueous solution of a water-soluble surfactant
becomes turbid. The optimized formula was diluted with distilled water to 100 times and placed in a
water bath where the temperature was increased gradually (1.0 ◦C/min). Cloudpoint was recorded as
the temperature at which the diluted formulation turned cloudy (visual perception).
2.7.4. Effect of Dilution on Droplet Size and PDI
The optimized formulation was evaluated for robustness of dilution. The pre-concentrate was
diluted to 50, 100, 500, and 1000 times by distilled water in 100 mL Erlenmeyer-beakers with continuous
stirring at 37± 1 ◦C. Distribution parameters were measured using the dynamic light scattering method
as described above (Section 2.3).
2.7.5. Long-Term Physical Stability of Nanoemulsions
0.2 mL of optimized BSNEDDS was dropped by automatic pipette into 100 mL distilled water at
37± 1 ◦C, with continuous stirring for 1 h at approximately 500 rpm (IKA RT-5 power heatable magnetic
stirrer). After several minutes of mild stirring, an intrinsic droplet size and PDI were measured by Zetasizer
Nano ZS™ (for setting parameters see Section 2.3). The Erlenmeyer flask with stopper was stored at room
temperature and protected from direct sunlight until further investigation. Determinations were performed
at 37.0 ◦C throughout the storage time (1 day, 3 days, 7 days, 14 days, 21 days, 28 days).
2.7.6. Atomic Force Microscopy (AFM)
Sample Preparation for AFM Imaging
The BSNEDDS pre-concentrate was diluted 107-fold with distilled water. Five µL of this emulsion
was dropped on a freshly cleaved mica surface and was frozen by pouring approximately 30 mL liquid
N2 onto it. The sample was immediately placed in the lyophilizator chamber (CoolSafe™ 110-04 freeze
dryer, ScanVac, Lillerød, Denmark), pre-cooled to −60 ◦C, and lyophilized at the following parameters:
10 min freezing at −40 ◦C, then drying at 0.020 hPa vacuum chamber pressure for 18 h. The shelf
temperature was set at 15 ◦C for 1 h, 20 ◦C for 1 h, 30 ◦C for 8 h, and 40 ◦C for 4 h. Freeze-dried
samples were stored protected from light at ambient humidity at 25 ± 1 ◦C and examined within 4 h
of the end of the lyophilization process.
AFM Imaging and Analysis
Lyophilized samples were imaged in non-contact mode with a Cypher S instrument (Asylum
Research, Santa Barbara, CA, USA) at 1–2 Hz line-scanning rate in air using a silicon cantilever
(OMCL AC-160TS, Olympus, Tokyo, Japan) and oscillated at its resonance frequency (typically
300–320 kHz). Temperature during the measurements was 29 ± 1 ◦C. Images were analyzed by
using the built-in algorithms of the AFM driving software (IgorPro, WaveMetrics Inc., Lake Oswego,
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OR, USA). AFM amplitude-contrast images are shown in this paper. To determine height variations,
height-contrast data were used.
2.8. In Vitro Dissolution Study and Nanoemulsifying Ability Test of BSNEDDS
Dissolution testing was performed using the Hanson SR-8 Plus™ Dissolution Test Station (Hanson
Research, Los Angeles, CA, USA) by the paddle (United States Pharmacopeia apparatus 2) method at
50 rpm and 37± 0.2 ◦C. The formulations were screened in 500 mL of aqueous-based dissolution media
at pH 1.2 (Ph.Eur.9.) and pH 6.8 (Ph.Eur.9.). Pure baicalin and liquid BSNEDDS (equivalent to 5 mg of
baicalin) were exposed to the media, and at predetermined time-points, 5 mL of samples were withdrawn
and filtered from the media through 5 µm pore size membrane full-flow filters by Hanson AutoPlus
Multifill collector (Hanson Research). After every sampling, media replacement was accomplished with
5 mL of fresh buffer solution. Dissolution studies were completed in triplicate and the dissolved drug
content (%)± SD was analyzed by UV-Vis spectrophotometry at 279 nm against equivalent proportions
of excipients as blank. Withdrawn and filtered samples were characterized for droplet size and PDI as
described for liquid BSNEDDS in Section 2.3. 24 h of visual observation was fulfilled for any precipitation
or phase separation. The hydrophobic API favours being dissolved in the droplet of nanoemulsion, and this
state (preceded by filtration and dispergation) was measured by UV-Vis spectroscopy.
3. Results
3.1. Solubility Studies
Oil represents one of the most important excipients in SNEDDS formulations. To achieve optimal
drug loading, it is essential to choose the oil having the greatest solubilizing capacity [26]. Amongst the
various oils that were examined, Peceol® showed the highest solubilizing capacity (719.1± 83.05 µg/mL)
for baicalin, followed by Labrafac™ Lipophile WL 1349 and Maisine® CC. The investigated natural oils
were unsuitable for dissolving the target amount of baicalin. This observation is in accordance with the
existing literature [27]. Based on solubility studies, Peceol® was the ideal choice as an oily phase.
Selection of a surfactant depends on several factors, such as solubilizing capacity for the API,
the efficiency and rapidity of emulsification of the oil, and safety [28]. Non-ionic surfactants are
considered less toxic than ionic ones. Due to these considerations, we analyzed five non-ionic
surfactants with various hydrophilic-lipophilic balance (HLB) values. The highest solubility of baicalin
was obtained in Labrasol® (3609.4 ± 277.39 µg/mL) followed by Kolliphor® EL and Labrafil® M
1944 CS. Solubility studies are necessary, but conditions were not sufficient for selecting an emulgent,
so Kolliphor® EL, Labrafil® M 1944 CS, and Labrasol® were tested further for emulsification ability
(see Section 3.2) [29]. The role of the co-surfactant together with the surfactant is to lower the interfacial
tension, and to facilitate dissolving large amounts of API in the oily phase [26]. Drug absorption and
dispersibility can also be improved by prudent selection of co-emulgent [30]. Transcutol® P, an ether
derivate, revealed extremely high (13742.5 ± 691.74 µg/mL) solubilizing capacity, and was therefore
chosen as a co-surfactant for further investigations. The results of the solubility study are presented in
Figure 1.
Pharmaceutics 2018, 10, 275 7 of 17
Pharmaceutics 2018, 10, x FOR PEER REVIEW  7 of 17 
 
 
 
Figure 1. Thermodynamic solubility of baicalin in various oils (red), emulgents (blue), co-emulgents 
(green), and distilled water (gray). (Mean ± SD; n = 3). 
3.2. Screening of Surfactants for Emulsifying Ability 
Three emulgents with various molecular structures and HLB-values were chosen in order to 
screen their ability to emulsify the oily phase by droplet size (Figure 2A) and turbidity analysis 
(Figure 2B). The droplet size of emulsions of Labrasol® and Kolliphor® EL demonstrated reduction 
with increased emulgent content, while Labrafil® M 1944 CS did not indicate any significant droplet 
size shift when mixed with various oil ratios. All Labrasol®-containing formulations demonstrated 
unacceptable self-emulsification efficiency and turbid systems were generated. Kolliphor® EL 
showed the best emulsification ability and produced the most desired droplets with 151 ± 1.2871 nm 
at Peceol® Kolliphor® EL 1:6 w/w ratio. Turbidity analysis revealed a clear augmentation of 
transmittance with increased oil:emulgent ratios for Kolliphor® EL and Labrasol®, however Labrafil® 
M 1944 CS expressed a sharp decline. It has been reported that the required HLB value to form o/w 
nanoemulsion is greater than 10 [31]. The very poor emulsifying ability of Labrafil® M 1944 CS can 
be attributed to its low HLB-value (HLB = 3). Labrasol® (HLB = 14) exhibited better affinity for the oil 
phase compared to Labrafil® M 1944 CS, although the best compatibility was shown with Kolliphor® 
EL (HLB = 12). This indicates that nanoemulsification was also influenced by other factors besides 
HLB value, such as the chemical structure, saturation, and chain length of the surfactant [32]. 
Furthermore, it was demonstrated that Kolliphor® EL has an inhibitory impact on different CYP-
enzymes and on intestinal P-glycoprotein, which are desirable to enhance the bioavailability [33]. We 
have selected Kolliphor® EL as giving the greatest transmittance and lowest droplet size with 
increased oil:emulgent ratios. In consideration of the aforementioned results and observations, we 
can conclude that Peceol®, Kolliphor® EL, and Transcutol® P is the best choice for designing baicalin 
containing SNEDDS. 
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(green), and distilled water (gray). (Mean ± SD; n = 3).
3.2. Screening of Surfactants for Emulsifying Ability
Three emulgents with various molecular structures and HLB-values were chosen in order to
screen their ability to emulsify the oily phase by droplet size (Figure 2A) and turbidity analysis
(Figure 2B). The droplet size of emulsions of Labrasol® and Kolliphor® EL demonstrated reduction
with increased emulgent content, while Labrafil® M 1944 CS did not indicate any significant droplet
size shift when mixed with various oil ratios. All Labrasol®-containing formulations demonstrated
unacceptable self-emulsification efficiency and turbid systems were generated. Kolliphor® EL showed
the best emulsification ability and produced the most desired droplets with 151 ± 1.2871 nm at Peceol®
Kolliphor® EL 1:6 w/w ratio. Turbidity analysis revealed a clear augmentation of transmittance with
increased oil:emulgent ratios for Kolliphor® EL and Labrasol®, however Labrafil® M 1944 CS expressed
a sharp decline. It has been reported that the required HLB value to form o/w nanoemulsion is greater
than 10 [31]. The very poor emulsifying ability of Labrafil® M 1944 CS can be attributed to its low
HLB-value (HLB = 3). Labrasol® (HLB = 14) exhibited better affinity for the oil phase compared to
Labrafil® M 1944 CS, although the best compatibility was shown with Kolliphor® EL (HLB = 12).
This indicates that nanoemulsification was also influenced by other factors besides HLB value, such
as the chemical structure, saturation, and chain length of the surfactant [32]. Furthermore, it was
demonstrated that Kolliphor® EL has an inhibitory impact on different CYP-enzymes and on intestinal
P-glycoprotein, which are desirable to enhance the bioavailability [33]. We have selected Kolliphor®
EL as giving the greatest transmittance and lowest droplet size with increased oil:emulgent ratios.
In consideration of the aforementioned results and observations, we can conclude that Peceol®,
Kolliphor® EL, and Transcutol® P is the best choice for designing baicalin containing SNEDDS.
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with Peceol® at different w/w ratios characterized by droplet size (A) and transmittance (B) analysis.
(Mean± SD; n = 3).
3.3. Construction of Ternary Phase Diagram
The ternary phase diagram of different formulations of SNEDDS, which was prepared by
varying the concentration of Peceol®, Kolliphor® EL, and Transcutol® P, is demonstrated in Figure 3.
The ternary phase diagram was constructed based on solubility and emulsification studies to identify
the nanoemulsifying region (Z-avg < 200 nm, T% > 90%), and the composition also helps to determine
the concentration range of components for the formation of a nanoemulsion. Compositions containing
more than 22% oil phase were found to be out of the nanoemulsifying region. It was observed that at
least 40% surfactant is required for producing droplets under 200 nm.
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3.4. Opt mization of SNEDDS Pre-concentrates
Independent variables and their levels and dependent variables with goals used in Face-centered
experimental design are indicated in Table 1. Thirteen experiments were designed to understand the
influe ce of formulation variables (oil:Smix and emulgent:co-emulgent ratios) affecting droplet size,
transmittance, zeta-potential, and PDI (Table 1). The values of responses Y1 (Z-avg ( m)), Y2 (Transmittance
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(%)), Y3 (Zeta-potential (mV)), and Y4 (PDI) ranged from 20.3 to 200.8 nm, 78.7 to 100%,−33.8 to−15.9,
and 0.25 to 0.69, respectively. The ratio of maximum to minimum for responses Y1, Y2, Y3, and Y4 was
found to be 9.892, 1.271, 0.47, and 2.76, respectively. Power transformation was not required for these
responses and no aliases were found for the Quadratic model, and in all cases the Sequential Model Sum
of Squares detected the Quadratic model as being significant. The models were validated by one-way
analysis of variance (ANOVA), lack of fit, and R2 tests. The Model F values for responses Y1, Y2, Y3, and Y4
were 120.36, 66.24, 50.03, and 47.72, respectively, which implied that each model was significant. The final
polynomial equations and a summary of the regression analysis on all the responses are presented in
Table 2. The main effects (b1, b2) represent the average result of changing one variable at a time from
its low level to its high level while the other is kept fixed. The interaction terms (b12) show how Y1–Y4
change when two variables are simultaneously changed, while the quadratic terms (b11, b22) symbolize
nonlinearity. The positive sign of the coefficients indicates a synergistic effect on responses, while the
negative sign expresses an antagonistic effect. Our analysis also revealed non-significant lack of fit test
results (p > 0.05) for all the measured responses, which strengthened the reliability of the models.
Table 1. Independent variables and their levels (A) and dependent variables with goals (B) used in
face-centered experimental design.
(A)
Independent Variables Symbol
Levels
−1 0 +1
Oil:Smix ratio X1 1:8 1:6 1:4
Emulgent:co-emulgent
ratio X2 1:1 2:1 3:1
(B)
Dependent Variables Symbol Goal
Z-avg (nm) Y1 Y1 < 200 nm
Transmittance (%) Y2 Y2 > 90%
Zeta-potential (mV) Y3 Y3 > ±20 mV
Polydispersity index (PDI) Y4 Y4 < 0.400
Analysis of standardized main effects (only significant values p < 0.05 are discussed) showed
that droplet size (Y1) was affected by the synergistic effect of oil:Smix ratio, antagonistically influenced
by emulgent:co-emulgent ratio, the interaction term between oil:Smix and emulgent:co-emulgent
ratio, and quadratic terms of oil:Smix ratio. Transmittance (Y2) was synergistically affected by
emulgent:co-emulgent ratio and interaction between oil:Smix and emulgent:co-emulgent ratio, and an
antagonistic effect was found with oil:Smix ratio. In the case of Zeta potential (Y3), we found
a positive correlation with oil:Smix ratio and its quadratic term, and a negative correlation with
emulgent:co-emulgent ratio. PDI (Y4) showed a significant synergistic effect with oil:Smix ratio and
emulgent:co-emulgent ratio. Based on these results, it is obvious that all the factors contribute in
determining the characteristics of SNEDDS.
Table 2. Summary of results of regression analysis for responses Z-avg, Transmittance, Zeta-potential,
and PDI with R2, Adj-R2, and Pred-R2 tests (statistical significance indicated by * (p < 0.05)).
Source Z-avg (nm) Transmittance (%) Zeta-Potential (mV) PDI
b0 +97.24 +96.74 −27.61 +0.46
b1 +67.77 * −8.33 * +1.05 * +0.17 *
b2 −21.00 * +1.63 * −4.87 * +0.030 *
b12 −14.30 * +2.45 * −0.43 +0.045 *
b11 −14.91 * −5.58 +6.54 * −0.045
b22 +13.99 +0.72 −0.21 +0.035
R2 0.9885 0.9793 0.9728 0.9730
Adj-R2 0.9803 0.9645 0.9533 0.9537
Pred-R2 0.8887 0.8222 0.7732 0.9047
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Response surface method (RSM) designs help to quantify the relationships between one or
more measured responses and the vital input factors. The generated 3D plots show how any of
two factors affects the response. Figure 4A displays the effect of oil:Smix (X1), emulgent:co-emulgent
(X2), and their interaction on droplet size (Y1). When both oil:Smix (1:8) and emulgent:co-emulgent
were low (1:1), a mean droplet size of 27.7 ± 0.12 nm was observed. By increasing oil content while
keeping X2 at 1:1, droplet size was increased to 200.8 ± 1.64 nm. As the amount of surfactant and
co-surfactant mixture increased, so decreased the droplet size. It can be attributed to the fact that
strong localization of surface-active agents at the oil–water interface reduces the interfacial free energy.
The higher the oil content, the more extensive the total interfacial area to be stabilized, and the
amount of surfactant molecules are not sufficient to cover the oil droplets and lower interfacial
tension at the oil–water interface. The lowest droplet size (20.3 ± 0.08) was achieved at a low
oil:Smix level (1:8) and at high emulgent:co-emulgent ratio (3:1). The 3D response surface plot of
transmittance is demonstrated in Figure 4B. Formulations are considered transparent if the percentage
transmittance is above 90%, which is due to the fact that droplet size is not larger than 25% of the
wavelength of incident light [34]. Low level (−1) of oil:Smix ratios were favourable for producing
perfectly transparent nanoemulsions (100% and 99.9%), irrespective of the emulgent:co-emulgent
ratio. As the amount of oil decreased in the formulation, the transmittance increased, and vice
versa. Examining the responses, the minimum transmittance value (78.7 ± 0.08%) was detected
at a high level of oil:Smix and at a low level of emulgent:co-emulgent. Figure 4C illustrates
the relationship between oil:Smix and emulgent:co-emulgent ratios on Zeta-potential. The lowest
Zeta-potential (−33.8 ± 0.83 mV) was observed at the middle level of oil:Smix and high level of
emulgent:co-emulgent ratio. This electrokinetic potential was decreased by decreasing the ratio of
co-surfactant. This phenomenon might be explained by the insufficient co-surfactant concentration,
because the co-surfactant plays a special role in reduction of interfacial tension and providing flexibility
of the interfacial film [26]. The highest Zeta-potential (−15.9 ± 0.72) was detected at high oil:Smix and
low emulgent:co-emulgent level. The negative surface charge of dispersed nanoemulsions can be
explained by the chemical structure of Peceol. Peceol composed of glyceryl monooleate contains free
fatty acids, due to manufacturing or hydrolysis of glyceryl monooleate during storage. According to
the technical data sheet from the manufacturer, free glycerol content in Peceol is ≤ 6% and acid value
is 3.0 mg KOH/g, which meets the requirements of Eur. Ph. and United States Pharmacopoeia (USP).
Fatty acids in solutions can deprotonate to carboxylate anions [35]. The analysis of PDI (Figure 4D)
pointed out parallel relationships with the droplet size measurements and some differences as well.
The emulgent:co-emulgent ratio slightly influenced the polydispersity indices, while the effect of
various oil:Smix ratios were significant (p < 0.001) on PDI. The narrowest droplet size distribution (0.25)
was found when oil:Smix was at low level and emulgent:co-emulgent was high. We can conclude that
higher oil content of the pre-concentrate produces a nanoemulsion with wider droplet size distribution.
The desired PDI value should be less than 0.400, which implies a uniform particle size distribution [36].
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All the measured responses were graphically o ti ize sing the optimization module of the
software. With multiple responses it is neces ary t fi i here requirement simultaneously
meet the critical properties. By superimposing or o itical response contours on a contour
plot, it is possible to visually search for the best c e inimum and maximum acceptable
responses were determined according to the scientific liter t l t size < 2 0 nm, transmittance
>90%, Zeta-potential < ±20 mV, PDI < 0. . rl lot can be s en in Figure 4E, wh re the area
that satisfies the constraints is yellow, hile the area that does not meet criteria is grey. We selected our
optimized formulation from the middle of the yellow labelled area of the overlay plot. The optimized
SNEDDS contained Peceol® (14.29%, w/w), Kolliphor® EL (57.14%, w/w), and Transcutol® P (28.57%,
w/w). The predicted values for responses Y1, Y2, Y3, and Y4 were 59.63 nm, 99.51%, −26.50 mV,
and 0.36, respectively. Three batches of the optimized formulation were prepared and measured,
52.87 ± 0.5322 nm, 99.87 ± 0.18%, -25.42 ± 0.710 mV, and 0.335 ± 0.004. The predicted and observed
values of responses were in very close correlation, indicating the reproducibility of the model.
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3.5. Characterization of Optimized BSNEDDS
3.5.1. Droplet Size, Transmittance, PDI, and Zeta-Potential Measurements. Comparison of Loaded and
Unloaded SNEDDS
The droplet size, transmittance, PDI, and Zeta-potential of optimized BSNEDDS was measured.
It is a well-known fact that droplet size is an essential feature and can significantly influence the in vivo
fate of a nanoemulsion. The globule size of an emulsion also determines the rate and extent of drug
release [37]. The Z-avg was highly desirable with 86.75 ± 0.3553 nm, likewise the PDI value with
0.403 ± 0.007, indicating that the system had narrow droplet size distribution and indicating improved
drug dissolution kinetics. Transmittance of the diluted sample was 99.93 ± 0.13%. In general, when
the Zeta-potential of an emulsion is high (> ±20 mV), the repulsive forces exceed the attractive forces,
resulting in a relatively stable system. The long-term stability of a nanoemulsified system can be
estimated by examining the fluctuation of the Zeta-potential [38]. The Zeta-potential of optimized
BSNEDDS was −24.3 ± 1.44 mV and the specific conductivity was found to be 0.0135 ± 0.002 mS/cm.
We confirm that some features of unloaded SNEDDS have changed due to drug loading, but the
experiments supported the suitability of loaded SNEDDS to deliver baicalin. PDI and droplet size were
compared at two pH values in case of both unloaded and loaded SNEDDS (Table 3) to demonstrate
the effect of pH and highlight if there is any difference between the formulas due to drug loading.
From the results it is clear that pH has no effect on droplet size and PDI, but drug loading has a
consequence. The colloid dispersion formed from loaded SNEDDS undoubtedly meets the quality
criteria and characteristics for a nanoemulsion (droplet size < 200 nm, PDI < 0.40). It was pointed out
that the drug itself didn’t influence the self-dispersing process, as dilution with a dispersing media
self-emulsification takes place in seconds.
Table 3. Effect of pH and drug loading on Z-avg and PDI after dispergation of unloaded and loaded
Self-nanoemulsifying formulations (Mean ± SD; n = 3).
Z-avg (nm) ± SD
pH SNEDDS BSNEDDS
1.2 50.41 ± 0.321 84.93 ± 0.3235
6.8 52.84 ± 0.632 86.67 ± 0.2956
PDI ± SD
pH SNEDDS BSNEDDS
1.2 0.231 ± 0.01 0.321 ± 0.002
6.8 0.217 ± 0.01 0.347 ± 0.003
3.5.2. Determination of the Thermodynamic Solubility of Baicalin in Optimized SNEDDS
The thermodynamic solubility of baicalin in optimized SNEDDS was 2714.3 ± 113.8 µg/mL.
It indicated 40.5-times solubility improvement correlated with solubility in distilled water
(67.0 ± 1.6 µg/mL). The hydrophobic API favoured being dissolved in the droplet of nanoemulsion,
and this state (preceded by filtration and dispergation) was measured by UV-Vis spectroscopy.
3.5.3. Cloudpoint Measurement
A special property of non-ionic surfactants is cloudpoint, the temperature above which the
surfactant phase separates and precipitates out of solution. The cloudpoint should be higher than 37 ◦C
in the ideal case because of the risk of irreversible phase separation in the body [39]. The cloudpoint
for BSNEDDS was 71–73 ◦C, providing stabile nanoemulsion in vivo at physiological temperatures.
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3.5.4. Effect of Dilution on Droplet Size and PDI
After oral administration of SNEDDS, nanoemulsion formation upon dilution takes place in vivo.
It is a relevant aspect to demonstrate that uniform nanoemulsions are formed in terms of various dilutions,
and these nanoemulsified systems do not show any sign of phase separation or precipitation. The drug may
precipitate in vivo at higher dilutions, which might significantly affect drug absorption [40]. All emulsions
were found to be in the acceptable nanoemulsion region (Z-avg. < 200 nm, T > 90%, PDI < 0.4), proving their
robustness to dilution. After 24 h of inspection, neither phase separation, nor precipitation, was observed.
In vitro results showed that BSNEDDS in different dilutions form uniform nanoemulsions and drug
solubility in BSNEDDS was adequate (no precipitation).
3.5.5. Long-Term Physical Stability of Nanoemulsions
The long-term physical stability of BSNEDDS was evaluated by droplet size, PDI measurements,
and macroscopic emulsion observation for a month. There are a lot of various physicochemical
phenomena which can lead to the breakdown of a nanoemulsion (e.g., creaming, flocculation, Ostwald
ripening), but these undesirable mechanisms can be identified. According to our analysis there was no
significant change in droplet size and/or PDI over the investigated period compared to initial values.
The visual observation revealed no phase separation, creaming, or precipitation. The o/w baicalin
containing nanoemulsion demonstrated high physical stability. The results of the long-term stability
study are illustrated in Table 4.
Table 4. Results of long-term stability analysis of liquid baicalin loaded liquid self-nanoemulsifying
drug delivery systems (BSNEDDS) formula. (Mean ± SD; n = 3).
Storage Intervals (days) Z-avg (nm) PDI
0 81.24 ± 0.17 0.406 ± 0.007
1 80.14 ± 0.08 0.405 ± 0.006
5 79.23 ± 0.14 0.379 ± 0.002
7 82.37 ± 0.10 0.400 ± 0.002
21 79.53 ± 0.05 0.443 ± 0.003
28 80.86 ± 0.28 0.389 ± 0.003
3.5.6. Atomic Force Microscopy
Lyophilized nanodroplets were dispersed homogeneously on a mica surface, showing no
signs of aggregation (Figure 5A). They appeared as circular objects with smooth surfaces and a
rounded topography (Figure 5B), which corresponds well to what one would expect from a surface
adsorbed droplet. Height of particles followed a slightly right skewed distribution (Figure 5C).
Lack of outstandingly large particle sizes indicate that droplets did not coalesce during sample
preparation. Mean height of droplets (±SD) was 15.4 ± 9.0 nm, which was lower than the diameter
(52.87 ± 0.5322 nm) obtained from DLS data. This may stem from two factors: (1) Flattening of
emulsion droplets on the mica surface, or (2) the fact that DLS yields the hydrodynamic size of the
droplets, which is bigger than the real particle diameter. Since the diameter of surface adsorbed
droplets is about two times larger than their height (Figure 6A), at first sight one would think there was
a considerable flattening indeed. However, a tip convolution artefact on its own can result in this extent
of artefactual apparent widening of the vesicle diameter, with the tip radius being approximately 9 nm.
To estimate the diameter of the original fluid-phase emulsion droplets, volume of surface-adsorbed
droplets was determined. From this, the real diameter of fluid phase droplets could be calculated,
assuming that they have spherical shape and there is no volume change upon surface-adsorption.
Estimated fluid phase droplet radius showed an apparent normal distribution with 23.6 ± 12.0 nm as
mean ± SD (Figure 6B). This value falls somewhat closer to the DLS size. The differences between
them might be attributed to the hydrodynamic overestimation of particle size by the DLS method.
Pharmaceutics 2018, 10, 275 14 of 17
Pharmaceutics 2018, 10, x FOR PEER REVIEW  14 of 17 
 
 
Figure 5. (A) Atomic force microscopy (AFM) amplitude-contrast images of surface adsorbed 
lyophilized oil droplets. (B) The area marked by dashed line is shown. (C) Height distribution of 
droplets (n = 122). 
 
Figure 6. (A) Correlation between the height and diameter of surface-adsorbed oil droplets. (B) 
Histogram of estimated radius of oil droplets in the fluid phase. Estimation based on volume of 
surface-absorbed droplets (n = 122). 
3.6. In Vitro Dissolution Study and Nanoemulsifying Ability Test of BSNEDDS 
In vitro dissolution profiles of BSNEDDS pre-concentrate and baicalin in pH = 1.2 and pH = 6.8 
dissolution media are depicted in Figure 7. It was observed that baicalin loaded nanodroplets were 
rapidly dispersed in the media (within 5 min) irrespective of pH of the dissolution media, and 100% 
of baicalin was dissolved in nanodroplets. In contrast, the pure drug showed much lower dissolution 
rates for the initial period of 5 min at both pH values. It was proved that the dissolution rate of 
baicalin is significantly lower in the case of pH 1.2 correlated to pH 6.8, which can be explained by its 
pH-dependent solubility. 
5. (A) Atomic force microscopy (AFM) amplitude-contrast images of surface ad orbed lyophiliz
oil droplets. (B) The ar a marked by dashed line is shown. (C) H ight distribution of droplets (n = 122).
Pharmaceutics 2018, 10, x FOR PEER REVIEW  14 of 17 
 
 
Figure 5. (A) Atomic force microscopy (AFM) amplitude-contrast images of surface adsorbed 
lyophilized oil droplets. (B) The area marked by dashed line is shown. (C) Height distribution of 
droplets (n = 122). 
 
Figure 6. (A) Correlation between the height and diameter of surface-adsorbed oil droplets. (B) 
Histogram of estimated radius of oil droplets in the fluid phase. Estimation based on volume of 
surface-absorbed droplets (n = 122). 
3.6. In Vitro Dissolution Study and Nanoemulsifying Ability Test of BSNEDDS 
In vitro dissolution profiles of BSNEDDS pre-concentrate and baicalin in pH = 1.2 and pH = 6.8 
dissolution media are depicted in Figure 7. It was observed that baicalin loaded nanodroplets were 
rapidly dispersed in the media (within 5 min) irrespective of pH of the dissolution media, and 100% 
of baicalin was dissolved in nanodroplets. In contrast, the pure drug showed much lower dissolution 
rates for the initial period of 5 min at both pH values. It was proved that the dissolution rate of 
baicalin is significantly lower in the case of pH 1.2 correlated to pH 6.8, which can be explained by its 
pH-dependent solubility. 
6. (A) Correlation between the heig t and diameter of su face-adsorbed oil droplets. (B) Histogram
of estim ted radius of oil droplets in the fluid phase. Estimation based on volume of surface-absorbed
droplets (n = 122).
3.6. In Vitro Dissolution Study and Nanoemulsifying Ability Test of BSNEDDS
In vitro di solution profiles of BSNEDDS pre-concentrate and baicalin in pH = 1.2 and
pH = 6.8 dissolution media are depicted in Figure 7. It was observed that baicalin loaded nanodroplets
were rapidly dispersed in the media (within 5 min) irrespective of pH of the dissolution media,
and 100% of baicalin was dissolved in nanodroplets. In contrast, the pure drug showed much lower
dissolution rates for the initial period of 5 min at both pH values. It was proved that the dissolution
rate of baicalin is significantly lower in the case of pH 1.2 correlated to pH 6.8, which can be explained
by its pH-dependent solubility.
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